Sabbatinelli et al. [54] evaluated the levels of circulating miR-146a, miR-21-5p, and miR126-3p in COVID-19 patients that were treated with the monoclonal antibody Tocilizumab (TCZ), an IL-6 signaling inhibitor, to evaluate the role of these pro-inflammatory-linked miRNAs. This evidence concerns the gene IL6 and COVID-19.